VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI’.
Trial of live-attenuated vaccine VLA1553 was conducted in US, with high seroprotection rates observed in participants up to 180 days after vaccination. Study published in 'The Lancet'.
Trials for the vaccine, which International Vaccine Institute is developing in partnership with Bharat Biotech, are also expected to begin in Panama and Colombia by September.
Researchers from Chulalongkorn University in Thailand find that chikungunya strain identified in Thailand has mutations that originated in India and Bangladesh
BJP’s fate in the second phase of 2024 Lok Sabha election will be decided in Karnataka, Rajasthan, and Maharashtra, where it performed very well in 2019 but faces a stiff competition now.
The private lender's shares tumbled to be top Nifty 50 loser after India's central bank barred it from taking on new customers through online and mobile banking channels.
Another addition to military cooperation has been the Strategic Space Dialogue, inaugurated in Paris in 2023. Last month, India participated as an observer to France’s AsterX.
COMMENTS